Literature DB >> 10493504

14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myélome.

H Avet-Loiseau1, T Facon, A Daviet, C Godon, M J Rapp, J L Harousseau, B Grosbois, R Bataille.   

Abstract

Clonal plasma cells in monoclonal gammopathy of undetermined significance (MGUS) have been shown to bear copy number chromosome changes. To extend our knowledge of MGUS to structural chromosomal abnormalities, we have performed fluorescence in situ hybridization experiments with probes directed to the 14q32 and 13q14 chromosomal regions in 100 patients with either MGUS or smoldering multiple myeloma (SMM). 14q32 abnormalities were observed in at least 46% of patients with MGUS/SMM, with these abnormalities being present in the majority of clonal plasma cells. Whereas t(11;14)(q13;q32) occurs in 15% of MGUS/SMM patients, an incidence similar to that of overt multiple myeloma (MM) patients, translocation t(4;14)(p16;q32) is observed in only 2% of these cases [P = 0.002 for difference with t(11;14)], as compared with 12% in MM patients (P = 0.013). Monoallelic deletions of the 13q14 region were found in 21% of patients, with two types of situations. In half of the evaluable patients, and especially in patients with SMM, the deletion is present in the majority of clonal plasma cells, as in MM, whereas in the other half of the evaluable patients (essentially in MGUS patients), it is observed in subclones only. These data enable us to elaborate a plasma cell oncogenesis model from MGUS to MM.

Entities:  

Mesh:

Year:  1999        PMID: 10493504

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

Review 1.  Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  Curr Hematol Malig Rep       Date:  2010-04       Impact factor: 3.952

Review 2.  FGF receptor inhibitors: role in cancer therapy.

Authors:  Gennaro Daniele; Jesus Corral; L Rhoda Molife; Johann S de Bono
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

Review 3.  Signaling Pathways and Emerging Therapies in Multiple Myeloma.

Authors:  Vijay Ramakrishnan; Anita D'Souza
Journal:  Curr Hematol Malig Rep       Date:  2016-04       Impact factor: 3.952

4.  A practical approach to the detection of prognostically significant genomic aberrations in multiple myeloma.

Authors:  Zhong Chen; Bonnie Issa; Shiang Huang; Emily Aston; Jia Xu; Margaret Yu; Arthur R Brothman; Martha Glenn
Journal:  J Mol Diagn       Date:  2005-11       Impact factor: 5.568

5.  Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression.

Authors:  Weixin Wang; Meghan Corrigan-Cummins; Emily A Barber; Layla M Saleh; Adriana Zingone; Azam Ghafoor; Rene Costello; Yong Zhang; Roger J Kurlander; Neha Korde; Aldo M Roccaro; Irene M Ghobrial; Ola Landgren; Katherine R Calvo
Journal:  J Mol Diagn       Date:  2015-09-30       Impact factor: 5.568

Review 6.  Multistep tumorigenesis of multiple myeloma: its molecular delineation.

Authors:  Shinsuke Iida; Ryuzo Ueda
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

Review 7.  Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.

Authors:  Amit Agarwal; Irene M Ghobrial
Journal:  Clin Cancer Res       Date:  2012-12-05       Impact factor: 12.531

Review 8.  Molecular pathogenesis of multiple myeloma: basic and clinical updates.

Authors:  Marta Chesi; P Leif Bergsagel
Journal:  Int J Hematol       Date:  2013-02-28       Impact factor: 2.490

9.  8p21.3 deletion suggesting a probable role of TRAIL-R1 and TRAIL-R2 as candidate tumor suppressor genes in the pathogenesis of multiple myeloma.

Authors:  A Gmidène; A Saad; H Avet-Loiseau
Journal:  Med Oncol       Date:  2013-02-20       Impact factor: 3.064

10.  Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis.

Authors:  Alan H Bryce; Rhett P Ketterling; Morie A Gertz; Martha Lacy; Ryan A Knudson; Steven Zeldenrust; Shaji Kumar; Suzanne Hayman; Francis Buadi; Robert A Kyle; Philip R Greipp; John A Lust; Stephen Russell; S Vincent Rajkumar; Rafael Fonseca; Angela Dispenzieri
Journal:  Haematologica       Date:  2009-02-11       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.